Microbial production of natural sweeteners, diterpenoid steviol glycosides

US9284570B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9284570-B2
Application numberUS-201113306633-A
CountryUS
Kind codeB2
Filing dateNov 29, 2011
Priority dateNov 30, 2010
Publication dateMar 15, 2016
Grant dateMar 15, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to recombinant expression of a steviol or steviol glycosides biosynthetic pathway enzymes in cells and the production of steviol or steviol glycosides.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for producing steviol or steviol glycoside comprising: culturing an E. coli strain having balanced expression of (1) an upstream methylerythritol pathway (MEP) that produces isopentyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), with respect to (2) a downstream pathway that produces steviol or steviol glycoside from said IPP and DMAPP, the downstream pathway comprising a recombinantly expressed copalyl diphosphate synthase (CPS), kaurene synthase (KS), a geranylgeranyl diphosphate synthase (GGPPS) kaurenoic acid 13-hydroxylase (KAH) and kaurene oxidase (KO), and optionally one or more Stevia UDP glycosyl transferase enzymes; wherein said balanced expression is obtained by increasing or decreasing the expression level of a downstream pathway module and increasing or decreasing the expression level of an upstream pathway module together in E. coli , and identifying an E. coli strain with higher production of steviol or steviol glycoside and/or lower accumulation of indole as having balanced expression. 2. The method of claim 1 , wherein the copalyl diphosphate synthase (CPS) enzyme is a Stevia enzyme. 3. The method of claim 1 , wherein the kaurene synthase (KS) enzyme is a Stevia enzyme. 4. The method of claim 1 , wherein the GGPPS enzyme is a Taxus enzyme or a Stevia enzyme. 5. The method of claim 1 , wherein the upstream pathway module comprises dxs, idi, ispD, and ispF genes of the MEP pathway. 6. The method of claim 5 , wherein the upstream pathway module comprises dxs, idi, ispD and ispF genes of the MEP pathway expressed as the operon dxs-idi-ispD-ispF. 7. The method of claim 1 , wherein the downstream module comprises the gene encoding the copalyl diphosphate synthase (CPS) enzyme, the gene encoding the kaurene synthase (KS) enzyme and the gene encoding the GGPPS enzyme co-expressed on an operon. 8. The method of claim 1 , wherein the downstream module further comprises kaurene oxidase (KO) and kaurenoic acid 13-hydroxylase (KAH) enzymes co-expressed on an operon, optionally each as fusions with a cytochrome P450 reductase. 9. The method of claim 1 , wherein the expression of the upstream pathway module and the expression of the downstream pathway module are balanced by one or more of: increasing or decreasing promoter strengths, increasing or decreasing gene or operon copy number, and changing the position of genes within the module. 10. The method of claim 9 , wherein one or more operons is integrated into the E. coli genome. 11. The method of claim 1 , wherein the KAH and KO are Stevia enzymes. 12. The method of claim 11 , wherein the KAH and/or KO comprise catalytically active portions fused to a Stevia cytochrome P450 reductase enzyme. 13. The method of claim 12 , wherein the KAH and KO enzymes have an N-terminal truncation and contain the N-terminal peptide sequence MALLLAVF (SEQ ID NO: 16). 14. The method of claim 1 , further comprising recovering the steviol or steviol glycoside. 15. The method of claim 14 , wherein the steviol or steviol glycoside is recovered from the gas phase of the culture by adding an organic layer.

Assignees

Inventors

Classifications

  • Copalyl diphosphate synthase (5.5.1.12) · CPC title

  • Hydroxy-carboxylic acids · CPC title

  • using catalysts, e.g. selective catalysts · CPC title

  • Ent-kaurene oxidase (1.14.13.78) · CPC title

  • Algae (unicellular algae C12N1/12) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9284570B2 cover?
The invention relates to recombinant expression of a steviol or steviol glycosides biosynthetic pathway enzymes in cells and the production of steviol or steviol glycosides.
Who is the assignee on this patent?
Stephanopoulos Gregory, Ajikumar Parayil K, Massachusetts Inst Technology
What technology area does this patent fall under?
Primary CPC classification C12N15/8243. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).